SynthesisBMC urology2024

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran.

Zahra Goudarzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.